JPRN-UMIN000034933已完成未知
Prospective Registry of rivaroxaban management of cancer-associated venous thromboembolism study - PRIMECAST
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients who have passed at least 2 weeks from diagnosis of VTE to the start of anticoagulant therapy. 2.Patients to whom the study drugs are contraindicated (see the package inserts) 3.Patients with active hemorrhage at the time of diagnosis of VTE 4.Other patients who are judged to be inappropriate by the physician in charge Ex. Inability or unwillingness to comply with the study related procedures, or employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator, etc. 5.Patients who are unlikely to receive anticoagulant therapy over three months.
研究者
相似试验
招募中
2 期
Evaluating the efficacy and safety of rivaroxaban comparing to warfarin in patients with chronic thromboembolic pulmonary hypertension (CTEPH) following endartrectomy surgeryChronic Thrombo Embolic Pulmonary Hypertension(CTEPH).Chronic Thromboembolic Pulmonary Hypertension.I27. 24IRCT20151227025726N22Shahid Beheshti University of Medical Sciences96
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer ParticipantsVenous thromboembolism (VTE)MedDRA version: 19.0 Level: LLT Classification code 10066899 Term: Venous thromboembolism System Organ Class: 100000004866EUCTR2015-001630-21-GBJanssen-Cilag International N.V.841
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer ParticipantsEUCTR2015-001630-21-BEJanssen-Cilag International NV800
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer ParticipantsVenous thromboembolism (VTE)MedDRA version: 20.0 Level: LLT Classification code 10066899 Term: Venous thromboembolism System Organ Class: 100000004866EUCTR2015-001630-21-CZJanssen-Cilag International N.V.841
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer ParticipantsVenous thromboembolism (VTE)MedDRA version: 20.0Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 100000004866EUCTR2015-001630-21-DEJanssen-Cilag International N.V.800